Stevenage, UK based TessellateBio recently signed a collaboration and licensing deal with Boehringer Ingelheim targeting tumors dependent on alternative lengthening of telomeres (ALT) for their growth
CEO Andree Blaukat describes TessellateBio's focus on synthetic lethality and the science behind this lead area they have partnered with Boehring Ingelheim on, which seeks to interrupt some cancers' ability to harness telomeres to continuously replicate. The deal is potentially work in excess of €500 million. Plus addition programs, including one targeting SKP2.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.